The CXCR3/CXCR3 ligand axis: Friend or foe?

The Inflammatory Milieu of Tumors: Cytokines and Chemokines that Affect Tumor Growth and Metastasis

Volumn , Issue , 2012, Pages 88-98

  Li, Yanchun ^b   Fulton, Amy M ^a  

^a UNIVERSITY OF MARYLAND SCHOOL OF MEDICINE   (United States)

^b UNIVERSITY OF MARYLAND GREENEBAUM CANCER CENTER   (United States)

Author keywords

CXCL10; CXCL11; CXCL9; CXCR3; CXCR3L; I TAC; IP 10; Miq

Indexed keywords

EID: 84882719211     PISSN: None     EISSN: None     Source Type: Book    
DOI: 10.2174/978160805256111201010088     Document Type: Chapter

References (61)

1. Lazzeri E, Romagnani P. CXCR3-binding chemokines: novel multifunctional therapeutic targets. Curr Drug Targets Imm Endocr Metabol Disord 2005; 5:109-18.
2. Yates CC, Whaley D, Y-Chen A, Kulesekaran P, Hebda PA and Wells A. ELR-negative CXC chemokine CXCL11 (IP-9/I-TAC) facilitates dermal and epidermal maturation during wound repair. Amer J Pathol 2008; 173:643-652.
3. Arenberg DA, Kunkel SL, Polverini PJ, et al. Interferon-γ-inducible protein 10 (IP-10) is an angiostatic factor that inhibits human non-small cell lung cancer (NSCLC) tumorigenesis and spontaneous metastases. J Exp Med 1996; 184:981.
4. Kondo T, Ito F, Nakazawa H, Horita S, Osaka Y and Toma H. High expression of chemokine gene as a favorable prognostic factor in renal cell carcinoma. J Urol 2004; 171:2171-5.
5. Kunz, M, Toksoy A, Goebeler M, Engelhardt E, Brocker E, Gillitzer, R. Strong expression of the lymphoattractant CXC chemokine Mig is associated with heavy infiltration of T cells in human malignant melanoma. J Pathol 1999; 189:52-8.
6. Wendel M, Galani IE, Suri-Payer E and Cerwenka A. Natural killer cell accumulation in tumors is dependent on IFN-γ and CXCR3 ligands. Cancer Res 2008; 68:8437-8445.
7. Chu Y, Yang X, Xu W, Wang Y, Guo Z, Xiong S. In situ expression of IFN-γ-inducible T cell α chemoattractant in breast cancer mounts an enhanced specific anti-tumor immunity which leads to tumor regression. Cancer Immunol Immunother 2007; 56:1539-1549.
8. Erreni M, Bianchi P, Laghi L, et al. Expression of chemokines and chemokine receptors in human colon cancer. Methods Enzymol. 2009; 460:105-121.
9. Jiang Z, Xu Y, and Cai S. CXCL10 expression and prognostic significance in stage II and III colorectal cancer. Mol Biol Rep 2010;37:3029-3036.
10. Mlecnik B, Tosolini M, Pornpimol C, et al. Biomolecular network reconstruction identifies T cell homing factors associated with survival in colorectal cancer. Gastroenterol 2010; 138:1429-1440.
11. Ohtani H, Jin Z, Takegawa S, Nakayama T and Yoshie O. Abundant expression of CXCL9 (MIG) by stromal cells that include dendritic cells and accumulation of CXCR3+ T cells in lymphocyte-rich gastric carcinoma. J Pathol 2009; 217:21-31.
12. Naschberger E, Croner RS, Merkel S, et al. . Angiostatic immune reaction in colorectal carcinoma: impact on survival and perspectives for antiangiogenic therapy. Int J Cancer 2008; 123:2120-2129.
13. Specht K, Harbeck N, Smida J, et al. . Expression profiling identifies genes that predict recurrence of breast cancer after adjuvant CMF-based chemotherapy. Breast Cancer Res Treat 2009; 118:45-56.
14. Ruiz-Garcia E, Scott V, Machavoine C, et al. . Gene expression profiling identifies fibronectin I and CXCL9 as candidate biomarkers for breast cancer screening. Brit J Cancer 2010; 102:462-468.
15. Moriai S, Takahara M, Ogino T, et al. . Production of interferon-γ-inducible protein-10 and its role as an autocrine invasion factor in nasal natural killer/T cell lymphoma cells. Clin Cancer Res 2009; 15:6771-6779.
16. Winter D, Moser J, Kriehuber E, et al. . Down modulation of CXCR3 surface expression and function in CD8+ T cells from cutaneous T cell lymphoma patients. J Immunol 2007; 179:4272-82.
17. Tominaga M, Isashita Y, Ohta M, et al. . Antitumor effects of the MIG and IP-10 genes transferred with poly [D,L- 2,4-diaminobutyric acid] on murine neuroblastoma. Cancer Gene Ther 2007; 14:696-705.
18. Luster AD, Leder P. IP-10, a CXC chemokine, elicits a potent thymus-dependent antitumor response in vivo. J Exp Med 1993; 178:1057-1065.
19. Sgadari C, Angiolillo AL, Cherney BW, et al. . Interferon-inducible protein-10 identified as a mediator of tumor necrosis in vivo. Proc Natl Acad Sci 1996; 93:13791-13796.
20. Feldman AL, Friedl J, Lans TE, et al. R. Retroviral gene transfer of interferon-inducible protein 10 inhibits growth of human melanoma xenografts. Int J Cancer 2002; 99:149-153.
21. Pan J, Burdick MD, Belperio JA, et al. . CXCR3/CXCR3 ligand biological axis impairs RENCA tumor growth by a mechanism of immunoangiostasis. J Immunol 2006; 176:1456-1464.
22. Dorsey R, Kundu N, Yang Q, et al. . Immunotherapy with interleukin-10 depends on the CXC chemokines Inducible Protein-10 and Monokine Induced by IFN-γ. Cancer Res 2002; 62:2606-2610.
23. Walser TC, Ma X, Kundu N, Dorsey R, Goloubeva O. and Fulton AM. Immune-mediated modulation of breast cancer growth and metastasis by the chemokine Mig (CXCL9) in a murine model. J Immunother 2007; 30:490-498.
24. Petrai I, Rombouts K, Lasagni L, et al. . Activation of p38MAPK mediates the angiostatic effect of the chemokine receptor CXCR3-B. Int J Biochem 2008; 40:1764-1774.
25. Li Y and Fulton AM. The CXCR3/CXCL3 Axis in Cancer In: Fulton AM, Ed. Chemokine Receptors in Cancer, Humana Press 2009; , pp. 79-91.
26. Andersson A, Yang S-C, Huang M, et al. IL-7 promotes CXCR3 ligand-dependent T cell antitumor reactivity in lung cancer. J Immunol 2009; 182:6951-6958.
27. Fujita M, Zhu X, Ueda R, et al. . Effective immunotherapy against murine gliomas using type 1 polarizing dendritic cells-significant roles of CXCL10. Cancer Res 2009; 69:1587-1595.
28. Kang TH, Bae HC, Kim S-H, et al. Modification of dendritic cells with interferon-γ inducible protein-10 gene to enhance vaccine potency. J Gene Med 2009; 11:889-898.
29. Kryczek I, Banerjee M, Cheng P, et al. . Phenotype, distribution, generation and functional and clinical relevance of Th17 cells in the human tumor environment. Blood 2009; 114:1141-1149.
30. Shahabuddin S, Ji R, Wang P, et al. . CXCR3 chemokine receptor-induced chemotaxis in human airway epithelial cells: role of p38 MAPK and PI3K signaling pathways. Am J Cell Physiol 2006; 291:C34-9.
31. Dagan-Berger M, Feniger-Barish Avniel S, Wald H, et al. Role of CXCR3 carboxyl terminus and third intracellular loop in receptor-mediated migration, adhesion and internalization in response to CXCL11. Blood 2006; 107:3821-31.
32. Thompson BD, Jin Y, Wu KH, et al. . Inhibition of Gai2 activation by Gai3 in CXCR3-mediated signaling. J Biol Chem 2007; 282:9547-9555.
33. Lasagni, L., Francalanci, M., Annunziato, F., et al. . An alternatively spliced variant of CXCR3 mediates the inhibition of endothelial cell growth induced by IP-10, Mig and I-TAC and acts as functional receptor for platelet factor 4. J Exp Med 2003; 197:1537-1549.
34. Ehlert JE, Addison CA, Burdick MD, Kunkel SL and Strieter RM. Identification and partial characterization of a variant of human CXCR3 generated by posttranscriptional exon skipping. J Immunol 2004; 173:6234-6240,.
35. Sfriso P, Oliviero F, Calabrese F, et al. . Epithelial CXCR3-B regulates chemokines bioavailability in normal, but not in Sjogren's syndrome salivary glands. J Immunol 2006; 176:2581-2589.
36. Furuya M, Suyama T, Usui H, et al. l. Up-regulation of CXC chemokines and their receptors: implications for proinflammatory microenvironments of ovarian carcinomas and endometriosis. Human Path 2007; 38:1676-1687.
37. Muller A, Homey B, Soto H, et al. . Involvement of chemokine receptors in breast cancer metastasis. Nature 2001; 410:50-6.
38. Fulton AM. The chemokine receptors CXCR4 and CXCR3 in cancer. Curr. Oncol. Rep. 2009; 11:125-31.
39. Goldberg-Bittman L, Neumark E, Sagi-Assif O, et al. . The expression of the chemokine receptor CXCR3 and its ligand, CXCL10, in human breast adenocarcinoma cell lines. Immunology Letters 2004; 92:171-8.
40. Goldberg-Bittman L, Sagi-Assif O, Meshel T, et al. . Cellular characteristics of neuroblastoma cells: Regulation by the ELR-- CXC chemokine CXCL10 and expression of a CXCR3-like receptor. Cytokine 2005; 29:105-17.
41. Jones D, Benjamin RJ, Shahsafaei A, Dorfman DM. The chemokine receptor CXCR3 is expressed in a subset of Bcell lymphomas and is a marker of B-cell chronic lymphocytic leukemia. Blood 2000; 95:627-32.
42. Kawada K, Sonoshita M, Sakashita H, et al. Pivotal role of CXCR3 in melanoma cell metastasis to lymph nodes. Cancer Research, 2004; 64:4010-7.
43. Kawada K, Hosogi H, Sonoshita M, et al. . Chemokine receptor CXCR3 promotes colon cancer metastasis to lymph nodes. Oncogene 2007; 26:4679-4688.
44. Robledo MM, Bartolome RA, Longo N, et al. . Expression of functional chemokine receptors CXCR3 and CXCR4 on human melanoma cells. J Biol Chem 2001; 276:45098-105.
45. Engl T, Relja B, Blumenberg C, et al. Prostate tumor CXC-chemokine profile correlates with cell adhesion to endothelium and extracellular matrix. Life Sciences 2006; 78:1784-93.
46. Trentin L, Agostini C, Facco M, et al. . The chemokine receptor CXCR3 is expressed on malignant B cells and mediates chemotaxis. J. Clin Invest 1999; 104:115-21.
47. Klatte T, Seligson DB, Leppert JT, et al. . The chemokine receptor CXCR3 is an independent prognostic factor in patients with localized clear cell renal cell carcinoma. J Urol 2008; 179:61-66.
48. Ocana E, Delgado-Perez L, Campos-Caro A, et al. . The prognostic role of CXCR3 expression by chronic lymphocytic leukemia B cells. Haematologica 2007; 92:349-356.
49. Monteagudo C, Martin JM, Jorda E. and Llombart-Bosch A. CXCR3 chemokine receptor immunoreactivity in primary cutaneous malignant melanoma:correlation with clinicopathologic prognostic factors. J Clin Pathol 2007; 60:596-9.
50. Walser TC, Rifat S, Ma X, et al. . Antagonism of CXCR3 inhibits lung metastasis in a murine model of metastatic breast cancer. Cancer Res 2006; 66:7701-7707.
51. Ma X, Norsworthy K, Kundu N, et al. . CXCR3 expression is associated with poor survival in breast cancer and promotes metastasis in a murine model. Mol Cancer Ther 2009; 8:490-498.
52. Datta D, Flaxenburg JA, Laxmanan S, et al. . Ras-induced modulation of CXCL10 and its receptor splice variant CXCR3-B in MDA-MB-435 and MCF-7 cells: relevance for the development of human breast cancer. Cancer Res 2006; 66:9509-9518.
53. Aksoy MO, Yang Y, Ji R, et al. . CXCR3 surface expression in human airway epithelial cells: cell cycle dependence and effect on cell proliferation. Am J Physiol Lung Cell Mol Physiol 2005; 290:L909-18.
54. Zipin-Roitman A, Meshel T, Sagi-Assif O, et al. . CXCL10 promotes invasion-related properties in human colorectal carcinoma cells. Cancer Res 2007; 67:3396-3405.
55. Cambien B, Karimdjee BF, Richard-Fiardo P, et al. Organ-specific inhibition of metastatic colon carcinoma by CXCR3 antagonism. Brit J Cancer 2009; 100:1755-1764.
56. Rubie C, Kollmar O, Frick VO, et al. Differential CXC receptor expression in colorectal carcinomas. Clin Immunol 2008; 68:635-44.
57. Shen H, Schuster R, Lu B, Waltz SE and Lentsch AB. Critical and opposing roles of the chemokine receptors CXCR2 and CXCR3 in prostate tumor growth. Prostate 2006; 66:1721-1728.
58. Nagpal ML, Davis J. and Lin T. Overexpression of CXCL10 in human prostate LnCaP cells activates its receptor (CXCR3) expression and inhibits cell proliferation. Biochim Biophys Acta 2006; 1762:811-818.
59. Pradelli E, Karimdjee-Soilihi B, Michiels J-F, et al. . Antagonism of chemokine receptor CXCR3 inhibits osteosarcoma metastasis to lungs. Int J Cancer 2009; 25:2586-2594.
60. Datta D, Contreras AG, Grimm M, Waaga-Gasser AM, Briscoe DM and Pal S. Calcineurin inhibitors modulate CXCR3 splice variant expression and mediate renal cancer progression. J Am Soc Nephrol 2008; 19:2437-2446.
61. Gacci M, Serni S, Lapini A, et al. . CXCR3-B expression correlates with tumor necrosis extension in renal cell carcinoma. J Urol 2009; 181:843-848.